Ischemic Stroke
Conditions
Brief summary
Thrombolysis and endovascular thrombectomy are the most efficient treatments for acute ischemic stroke patients in time window. Although sufficient recanalization after thrombectomy is more than 80%, HERMES study indicated that nearly half of the ischemic stroke patients under thrombectomy suffered obvious disability. Artery reocclusion, hemorrhagic transformation, and no-reflow phenomenon are among the most important reasons of poor prognosis of acute ischemic stroke patients. The investigators speculate that a combination of argatroban, edaravone, and glucocorticoid may be helpful in preventing artery reocclusion, hemorrhagic transformation, and no-reflow phenomenon. This study intends to explore the safety, feasibility and efficacy of thrombectomy with sufficient recanalization bridged by intra-arterial cocktail therapy in acute ischemic stroke patients.
Interventions
DRUGintra-arterial cocktail therapy
Intra-arterial administration of argatroban (0.2-0.3 mg/min), dexamethasone (0.1 mg/min) and edaravone (0.3 mg/min) for 30 to 60 minutes after thrombectomy.
Sponsors
Hui-Sheng Chen
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥18 years. 2. Patients who presented with acute ischemic stroke and a large vessel occlusion in the anterior circulation and met the criteria of mechanical thrombectomy. 3. Sufficient recanalization （TICI 2b-3）within 7 hours of stroke onset. 4. The availability of informed consent.
Exclusion criteria
1. insufficient recanalization（TICI \< 2a）after endovascular treatment; 2. Hemorrhagic stroke: cerebral hemorrhage, subarachnoid hemorrhage. 4\. Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia （ \<100000/mm3）. 5\. Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis. 6\. Severe uncontrolled hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure over 110 mmHg). 7\. Patients with contraindication or allergic to any ingredient of drugs in our study. 8\. Unsuitable for this clinical studies assessed by researcher.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of favorable outcome | 90 days | favorable outcome is defined as mRS 0-2 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of excellent outcome | 90 days | excellent outcome is defined as mRS 0-1 |
| proportion of early neurological improvement | 48 hours | early neurological improvement is defined as more than 4 decrease in NIHSS |
Other
| Measure | Time frame | Description |
|---|---|---|
| incidence of symptomatic intracranial haemorrhage | 48 hours | intracranial haemorrhage is defined as more than 4 increase in NIHSS caused by intracranial bleeding |
Countries
China
Outcome results
None listed